


Radiopharmaceuticals Hotter Than Ever



YEAR	EVENT TYPE	DETAILS
2016		
06.16	FDA Approval	Product: NETSPOT: Gallium68 Dotatate Kit Indication: Neuroendocrine Tumor Detection Company: Advanced Accelerator Applications
06.16	FDA Approval	Product: Axumin (Fluciclvine 18F) Indication: Prostate Cancer Company: Blue Earth Diagnostics (now Bracco Imaging)
2017		
04.17	License Agreement	Product: Flurpiridaz F 18 Indication: Coronary Artery Disease (CAD) Companies: Lantheus, GE Healthcare
05.17	Acquisition	Acquirer: Sofie Biosciences Acquired: Zevacor Pharma
10.17	Acquisition	Acquirer: Novartis Acquired: Advanced Accelerator Applications for \$3.9B
2018		
01.18	FDA Approval	Product: Lutathera Indication: Treatment of Neuroendocrine tumors Company: Advanced Accelerator Applications (Novartis)
05.18	Licensing	Product: Investigational radiohybrid-targeted PSMA targets for prostate cancer Acquirer: Blue Earth Licensee: Scintomics
11.18	Launch	Product: LYMPHOSEEK (Tc 99m tilmanocept) Indication: Lymph Node Solid Tumor Company: Norgine B.V.
2019		
01.19	Launch	Product: Illumet Microsite Kit (For the Preparation of 68Ga-PSMA) Indication: Prostate Cancer Company: Telix Pharmaceuticals
06.19	Licensing	Product: All FAPI precursor Indication: Oncology Companies: Sofie Biosciences with University of Heidelberg
06.19	Merger	Companies: Jubilant Pharma Radiopharmaceutical Drug Development and Manufacturing + Jubilant Pharma Radio Pharmacy New Entity: Jubilant Radiopharma
08.19	Acquisition	Acquirer: Bracco Imaging Acquired: Blue Earth Diagnostics
10.19	Partnership	Product: GalliProst Indication: Prostate Cancer Companies: GE Healthcare and Theragnostics
10.19	Merger	Companies: Fuzionaire Diagnostics and Japan Medical Isotope Technology Development K.K. New Entity: Fuzionaire Radioisotope Technologies K.K.
10.19	Acquisition	Acquirer: Lantheus Acquired: Progenics
10.19	Strategic Collaboration	Companies: Sofie Biosciences signs with ABX Advanced Biochemical Compounds GmbH for the production and distribution of all FAPI products
2020		
03.20	FDA Approval	Product: Pulmotech™ MAA Indication: Lung scintigraphy, Scintigraphy of peritoneovenous shunt Company: Curium
03.20	Acquisition	Acquirer: Curium Acquired: Zevacor Molecular
05.20	FDA Approval	Product: Tauvid (flortaucipir F-18) Indication: Cognitive Impairment Company: Avid Radiopharmaceuticals
09.20	RPDD Status Granted	Product: ⁶⁴ Cu-SARTATE™ Indication: Neuroblastoma Company: Clarity Pharmaceuticals
09.20	Capital Hill Briefing	Company: SNMMI and Coalition Partners
09.20	FDA Approval	Product: Detectnet™ (copper Cu 64 dotatate injection) Indication: Neuroendocrine Tumors Company: RadioMedix and Curium
09.20	NDA Submission	Product: PyL™ (18F-DCFpyL) Indication: Prostate Cancer Company: Lantheus Holdings
10.20	Series A Financing	Company: RayzeBio
11.20	Collaboration	Companies: Fusion Pharmaceuticals and AstraZeneca for development and commercialization of next-generation radiopharmaceuticals and combination therapies
11.20	Partnership	Companies: SOFIE Biosciences and Jubilant Radiopharma
11.20	FDA Clearance	Product: Automated Bone Scan Index Software Indication: Prostate Cancer Company: Lantheus Holdings
12.20	Financing	Company: RayzeBio